In the UK it is thought unused prescription medications cost the NHS around £300m and medication adherence problems, while in the US the problem is responsible for up to $300bn in avoidable healthcare costs. Proteus Health, whose "chip-in-a-pill" collaboration with Otsuka was accepted by the US FDA earlier this month, has urged the UK NHS to follow suit and "think about the way they deliver care", adding "it's not sustainable to keep going the way we are". The company is also working on a new drug for hepatitis C that it hopes will be available in Britain within two years.
Proteus Health, whose "chip-in-a-pill" collaboration with Otsuka was accepted by the US FDA earlier this month, has urged the UK NHS to follow suit and "think about the way they deliver care", adding "it's not sustainable to keep going the way we are". The company is also working on a new drug for hepatitis C that it hopes will be available in Britain within two years.